Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One Patient's lifeline: donor t cells take on EBV lymphoma

NCT ID NCT06391814

Disease control Sponsor: Ciusss de L'Est de l'Île de Montréal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a personalized treatment for a young adult with a severe EBV-related lymphoma that occurred after a stem cell transplant. The patient received up to four infusions of specially grown immune cells from their original stem cell donor. The goal was to see if these cells could safely control the lymphoma and improve the body's ability to fight the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EBV-specific T cells (donor-derived immune cells)
What this could lead to
If successful, this approach could offer a way to control EBV-related lymphoma after a stem cell transplant without causing severe graft-versus-host disease.
What could go wrong
This was a single-patient study, so results may not apply to others. The treatment carries risks like graft-versus-host disease or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Jan 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Capacity to provide informed consent 2. Age ≥ 18 3. Negative serum pregnancy test and use of effective contraception method. Exclusion Criteria: 1. Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath) 2. Pregnancy 3. Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome. 4. Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV associated lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

EBV-positive T-cell lymphoproliferative disorder of childhood Epstein-Barr virus-associated lymphoproliferative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV associated lymphoma

Contacts and locations

Locations

  • Ciusss-Emtl

    Montreal, Quebec, H1T 2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.